BridgeBio Oncology Therapeutics, Inc. BBOT 深 沪
等待开盘 07-02 09:30:00 美东时间
7.80
+0.180
+2.36%
华盛通- 最 高8.0754
- 今 开7.62
- 成交量 47.94万股
- 最 低 7.575
- 昨 收 7.62
- 总市值 6.25亿
- 52周最高 14.87
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 7.00
- 委 比 80.08%
- 总股本 8010.71万
- 历史最高 14.87
- 量 比 1.10
- 振 幅 6.57%
- 历史最低 7.00
- 每 手 1
- 风险率 1.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 阿斯麦获美银、富国上调目标价最高至2345美元；Needham上调美光科技目标价从500美元升至1550美元
今日重点评级关注：Baird：维持Regenxbio"跑赢大市"评级，目标价从27美元升至32美元；古根海姆：维持Tenax Therapeutics"买入"评级，目标价从34美元升至40美元
06-23 13:48
Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22
Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $22.
06-23 01:34
BridgeBio Oncology Q1 EPS $(526.11) Down From (54.230) YoY,
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(526.11).This is a 870.15 percent decrease over losses of $(54.23) per share from the same period last year.
05-13 05:54
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Canaccord Genuity Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23
Canaccord Genuity analyst John Newman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.
05-11 19:51
FDA Grants BridgeBio Oncology Therapeutics Fast Track Designation To BBO-11818
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumorsUpdated Phase 1 clinical data are expected in the second half
04-21 04:07
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
HC Wainwright & Co. Maintains Buy on BridgeBio Oncology, Raises Price Target to $29
HC Wainwright & Co. analyst Robert Burns maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and raises the price target from $27 to $29.
03-06 20:13
BridgeBio Oncology Q4 EPS $(0.49) Beats $(0.56) Estimate
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.56) by 13.12 percent.
03-06 05:10
美股大行评级 | 杜邦、吉利德科学、Cloudflare、Saia获多家大行上调目标价；Datadog、Robinhood、Klaviyo、Lyft等遭多家大行下调目标价
今日重点评级关注：Benchmark：维持Klaviyo"买入"评级，目标价从30美元升至33美元；富国银行：维持Cloudflare"超配"评级，目标价从265美元升至270美元
02-12 14:02
